Impact of Intrapatient Immunosuppression Variability in Renal Transplantation Outcomes: A Systematic Review and Meta-analysis.

TransplantationJun 23, 2026 (epub)
Clinical ResearchNephrologyOpen access

Sherene Lattimore, Anastasia Chambers, Isabella Angeli-Pahim et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the impact of intrapatient variability (IPV) in drug concentrations on renal transplantation outcomes. Analyzing 41 studies, the findings indicated that patients with low IPV had a 44% lower risk of acute rejection compared to those with high IPV (RR = 0.56), and high IPV was associated with an increased risk of graft loss (HR = 2.42).

Key findings

  • Patients with low IPV had a 44% lower risk of acute rejection compared to those with high IPV (RR = 0.56).
  • High IPV was associated with an increased risk of graft loss, HR = 2.42 (95% CI, 1.70-3.46).
  • Numerous studies indicated high IPV correlates with increased rejection rates and worse allograft survival.

Why it matters

Understanding the role of intrapatient variability in immunosuppression can help clinicians identify modifiable risk factors that may improve transplantation outcomes, particularly regarding acute rejection and graft survival.

Source

PubMed · PMID 42318931Free full text on PubMed Central

Published in Transplantation. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.